Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Buy

Exponential Moving Average

Neutral

Relative Strength Index

Neutral

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Viridian Therapeutics, Inc. Common Stock (VRDN)

Services-medical Laboratories

https://www.viridiantherapeutics.com

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

221 CRESCENT STREET, BLDG. 17, SUITE 401
WALTHAM, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/18/2014

Market Cap

961,542,995

Shares Outstanding

52,590,000

Weighted SO

52,586,039

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

NUVL --.--%

DICE --.--%

ACLX --.--%

PCVX --.--%

CRNX --.--%

CYTK --.--%

GPCR --.--%

ICVX --.--%

PLRX --.--%

Beta

1.1490

Last Div

0.0000

Range

10.925-24.18

Chg

0.1300

Avg Vol

1051169

Mkt Cap

961542995

Exch

NASDAQ

Country

US

Phone

617 272 4600

DCF Diff

13.1307

DCF

1.7893

Div Yield

0.0000

P/S

3338.6910

EV Multiple

-3.7494

P/FV

1.8155

Div Yield %

0.0000

P/E

-4.2139

PEG

0.1177

Payout

0.0000

Current Ratio

15.8224

Quick Ratio

15.8224

Cash Ratio

2.9288

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

1112.7184

CCC

-1112.7184

Gross Margin

-2.5764

Op Margin

-870.7847

Pretax Margin

-791.8576

Net Margin

-791.8576

Eff Tax Rate

-0.3396

ROA

-0.3894

ROE

-0.4965

ROCE

-0.4569

NI/EBT

1.0000

EBT/EBIT

0.9094

EBIT/Rev

-870.7847

Debt Ratio

0.0349

D/E

0.0386

LT Debt/Cap

0.0320

Total Debt/Cap

0.0372

Int Coverage

288.9240

CF/Debt

-5.9756

Equity Multi

1.1064

Rec Turnover

0.0000

Pay Turnover

0.3280

Inv Turnover

0.0000

FA Turnover

0.0862

Asset Turnover

0.0005

OCF/Share

-1.9138

FCF/Share

-1.9209

Cash/Share

8.9479

OCF/Sales

-424.3264

FCF/OCF

1.0037

CF Coverage

-5.9756

ST Coverage

-41.2301

CapEx Coverage

-270.3673

Div&CapEx Cov

-270.3673

P/BV

1.8155

P/B

1.8155

P/S

3338.6910

P/E

-4.2139

P/FCF

-7.8392

P/OCF

-7.8639

P/CF

-7.8639

PEG

0.1177

P/S

3338.6910

EV Multiple

-3.7494

P/FV

1.8155

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 04, 10:00 Analyst Ratings for Viridian Therapeutics Benzinga Nov 14, 13:01 Where Viridian Therapeutics Stands With Analysts Zacks Investment Research Oct 31, 03:01 Viridian Therapeutics, Inc. (VRDN) Stock Jumps 5.2%: Will It Continue to Soar?

Revenue Product Segmentation